Sugi Predict

Sugi Predict / Compounds / SCHEMBL4358976

SCHEMBL4358976

SCHEMBL4358976

CC(C)(C)OC(=O)N1CCCC(Oc2ccc(N)cc2)C1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CHEK2 O96017 2/20 0.59
▸ USP30 Q70CQ3 2/20 0.53
▸ GPR119 Q8TDV5 3/20 0.50
▸ PDE4B Q07343 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.46
▸ PRMT5 O14744 1/20 0.46
▸ WDR77 Q9BQA1 1/20 0.46
▸ NR1H2 P55055 1/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ PIK3CD O00329 1/20 0.44
▸ MMP1 P03956 1/20 0.43
▸ MMP9 P14780 1/20 0.43
▸ MMP13 P45452 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15376614 0.92 GPR119 (0.58) CHEK2USP30GPR119PDE4BALDH1A1
SCHEMBL699609 0.92 GPR119 (0.58) CHEK2USP30GPR119PDE4BALDH1A1
SCHEMBL699608 0.92 GPR119 (0.58) CHEK2USP30GPR119PDE4BALDH1A1
SCHEMBL29964707 0.89 CHEK2 (0.55) CHEK2USP30GPR119PDE4BALDH1A1
SCHEMBL19838592 0.89 CHEK2 (0.55) CHEK2USP30GPR119PDE4BPRMT5
SCHEMBL29964863 0.89 CHEK2 (0.55) CHEK2USP30GPR119PDE4BALDH1A1
SCHEMBL19838590 0.89 CHEK2 (0.55) CHEK2USP30GPR119PDE4BPRMT5
SCHEMBL29280846 0.87 CHEK2 (0.54) CHEK2USP30GPR119PDE4BPRMT5
SCHEMBL30842586 0.87 CHEK2 (0.54) CHEK2USP30GPR119PDE4BPRMT5
SCHEMBL29280843 0.87 CHEK2 (0.54) CHEK2USP30GPR119PDE4BPRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233077-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2026-05-06 — — EP disclosed
US-12428373-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2025-09-30 — — US disclosed
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2023-05-11 — — US disclosed
US-11498896-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2022-11-15 — — US disclosed
US-20210147355-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2021-05-20 — — US disclosed
US-10633336-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2020-04-28 — — US disclosed
US-20180155283-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2018-06-07 — — US disclosed
EP-3233077-A1 DOPAMINE D2 RECEPTOR LIGANDS The Broad Institute Inc. (US) 2017-10-25 — — EP disclosed
WO-2016100940-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2016-06-23 — — WO disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 — — US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 — — US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 — — US disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 — — EP disclosed
EP-1507530-B1 DIAMINOTHIAZOLES AND USE THEREOF AS CDK4 INHIBITORS HOFFMANN LA ROCHE (CH) 2005-11-02 — — EP disclosed
EP-1507530-A1 DIAMINOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2005-02-23 — — EP disclosed
US-6818663-B2 AS INHIBITORS OF CYCLIN-DEPENDENT KINASE 4 (CDK4); ANTIPROLIFERATIVE AGENTS; FOR THERAPY OF CANCER, TUMORS HOFFMANN-LA ROCHES 2004-11-16 — — US disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 — — US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 — — WO disclosed
US-20040006058-A1 DIAMINOTHIAZOLES CHU XIN-JIE (US) 2004-01-08 — — US disclosed
WO-2003097048-A1 DIAMINOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2003-11-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155283-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, DRD3, ARRB1 CHEK2 1820/4885USP30 2810/4885GPR119 73/4885
US-11498896-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 CHEK2 3740/4885USP30 2018/4885GPR119 134/4885
US-10633336-B2 Dopamine D2 receptor ligands DRD2, ARRB1, DRD3 CHEK2 2241/4885USP30 2406/4885GPR119 145/4885
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 CHEK2 3740/4885USP30 2018/4885GPR119 134/4885
US-20210147355-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 CHEK2 3740/4885USP30 2018/4885GPR119 134/4885
US-12428373-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 CHEK2 3740/4885USP30 2018/4885GPR119 134/4885
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 CHEK2 63/4885USP30 2971/4885GPR119 1940/4885
US-20040006058-A1 DIAMINOTHIAZOLES CDK4, CDK1, CDK2 CHEK2 88/4885USP30 3539/4885GPR119 2534/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 CHEK2 58/4885USP30 3245/4885GPR119 3439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.